Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Shares Sold by Lazard Asset Management LLC

Lazard Asset Management LLC cut its position in shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRXGet Rating) by 67.7% in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 22,708 shares of the biopharmaceutical company’s stock after selling 47,567 shares during the quarter. Lazard Asset Management LLC’s holdings in Catalyst Pharmaceuticals were worth $159,000 at the end of the most recent quarter.

A number of other large investors have also modified their holdings of CPRX. Covestor Ltd grew its stake in Catalyst Pharmaceuticals by 768.0% during the 1st quarter. Covestor Ltd now owns 4,878 shares of the biopharmaceutical company’s stock valued at $40,000 after purchasing an additional 4,316 shares in the last quarter. Quantbot Technologies LP bought a new position in Catalyst Pharmaceuticals during the 1st quarter worth approximately $62,000. Point72 Hong Kong Ltd lifted its holdings in shares of Catalyst Pharmaceuticals by 63.0% in the 1st quarter. Point72 Hong Kong Ltd now owns 9,670 shares of the biopharmaceutical company’s stock worth $80,000 after purchasing an additional 3,738 shares during the last quarter. Blueshift Asset Management LLC bought a new stake in shares of Catalyst Pharmaceuticals in the 1st quarter worth approximately $91,000. Finally, Commonwealth Equity Services LLC lifted its holdings in shares of Catalyst Pharmaceuticals by 26.7% in the 2nd quarter. Commonwealth Equity Services LLC now owns 13,685 shares of the biopharmaceutical company’s stock worth $95,000 after purchasing an additional 2,885 shares during the last quarter. Institutional investors and hedge funds own 74.16% of the company’s stock.

Wall Street Analyst Weigh In

Several research firms recently commented on CPRX. Piper Sandler raised their target price on Catalyst Pharmaceuticals to $18.00 in a research report on Wednesday, November 16th. HC Wainwright raised their target price on Catalyst Pharmaceuticals from $12.00 to $18.00 and gave the stock a “buy” rating in a research report on Thursday, August 11th. Truist Financial lifted their price objective on Catalyst Pharmaceuticals from $12.00 to $17.00 and gave the company a “buy” rating in a research report on Thursday, August 11th. Roth Capital cut Catalyst Pharmaceuticals from a “buy” rating to a “neutral” rating and lifted their price objective for the company from $10.00 to $15.50 in a research report on Wednesday, August 24th. Finally, StockNews.com lowered Catalyst Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Wednesday, November 9th. One analyst has rated the stock with a hold rating and four have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, Catalyst Pharmaceuticals currently has a consensus rating of “Moderate Buy” and a consensus target price of $17.13.

Catalyst Pharmaceuticals Price Performance

Catalyst Pharmaceuticals stock opened at $15.56 on Tuesday. Catalyst Pharmaceuticals, Inc. has a one year low of $5.24 and a one year high of $17.22. The company has a market cap of $1.62 billion, a price-to-earnings ratio of 25.51 and a beta of 1.27. The firm has a 50-day moving average of $13.64 and a 200-day moving average of $10.93.

Insider Buying and Selling at Catalyst Pharmaceuticals

In other news, CFO Alicia Grande sold 60,000 shares of the firm’s stock in a transaction that occurred on Tuesday, November 15th. The shares were sold at an average price of $15.77, for a total transaction of $946,200.00. Following the transaction, the chief financial officer now directly owns 147,442 shares of the company’s stock, valued at $2,325,160.34. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In related news, CEO Patrick J. Mcenany sold 80,765 shares of the company’s stock in a transaction that occurred on Tuesday, September 13th. The shares were sold at an average price of $15.33, for a total transaction of $1,238,127.45. Following the sale, the chief executive officer now owns 4,849,452 shares of the company’s stock, valued at approximately $74,342,099.16. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CFO Alicia Grande sold 60,000 shares of the stock in a transaction on Tuesday, November 15th. The stock was sold at an average price of $15.77, for a total transaction of $946,200.00. Following the completion of the transaction, the chief financial officer now directly owns 147,442 shares in the company, valued at approximately $2,325,160.34. The disclosure for this sale can be found here. Insiders have sold a total of 631,793 shares of company stock valued at $9,517,739 in the last three months. 14.10% of the stock is currently owned by company insiders.

About Catalyst Pharmaceuticals

(Get Rating)

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.

Recommended Stories

Want to see what other hedge funds are holding CPRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRXGet Rating).

Institutional Ownership by Quarter for Catalyst Pharmaceuticals (NASDAQ:CPRX)

Receive News & Ratings for Catalyst Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalyst Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.